research & development
Scientific progress paired with compassion equals real results
Our pipeline
2023 - 2030
Antivenoms
Europe Anti-Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Snake Antivenom for Europe.
Indication: Treatment of envenoming caused by snakes distributed in Europe.
Phase: Phase II
Asia Anti-Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Snake Antivenom for Asia.
Indication: Treatment of envenoming caused by snakes distributed in Asia.
Phase: Phase I
South Africa Anti-Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Snake Antivenom for South Africa.
Indication: Treatment of envenoming caused by snakes distributed in South Africa.
Phase: Phase I
South America Anti-Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Snake Antivenom for South America.
Indication: Treatment of envenoming caused by snakes distributed in South America.
Phase: Phase I
North America Anti-Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Snake Antivenom for North America.
Indication: Treatment of envenoming caused by snakes distributed in North America.
Phase: Registration
North America Anti-Scorpion Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Scorpion Antivenom for North America.
Indication: Treatment of envenoming caused by Scorpion distributed in North America.
Phase: Registration
Coral Snake Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Coral Snake Antivenom.
Indication: Treatment of envenoming caused by snakes distributed in South America.
Phase: Phase III
South America Spider Antivenom
Description: Polyvalent F(ab’)2 Immunoglobulin Fragments (Equine), Spider Antivenom for America.
Indication: Treatment of envenoming caused by spider distributed in South America.
Phase: Phase I
Antivirals
SARS CoV-2 antiviral
Description: SARS-COV-2 Immune F(ab ́)2 (Equine).
Indication: Coadjuvant in the treatment of COVID-19.
Phase: Phase III
Ebola virus (EVD) Antivirus
Description: EVD Immune F(ab ́)2 (Equine).
Indication: Treatment of Ebola disease.
Phase: Phase I
Antitoxins
Diphtheria Antitoxin
Description: F(ab’)2 Immunoglobulin Fragments (Equine), Diphtheria Antitoxin.
Indication: Treatment of suspected diphtheria cases.
Phase: Phase I
Tetanus Antitoxin
Description: F(ab’)2 Immunoglobulin Fragments (Equine), Diphtheria Antitoxin.
Indication: Treatment of suspected diphtheria cases.
Phase: Phase I